Ex vivo lung perfusion (EVLP) is an established strategy to evaluate and optimize high-risk donor lungs that would otherwise be rejected for transplantation mainly due to the presence of edema or infection. Extracorporeal circuits may negatively affects pharmacokinetic (PK) of several drugs including antibiotics, thus exposing patients to risk of therapeutic failure or drug toxicity. The investigators set out to examine the concentration of imipenem in lung perfusate and in lung biopsy during EVLP, and its clinical impact.
Study Type
OBSERVATIONAL
Enrollment
30
University of Turin - Azienda Ospedaliera Città della Salute e della Scienza di Torino
Turin, Turin, Italy
RECRUITINGimipenem concentration
concentration of imipenem in lung perfusate and in lung biopsy during EVLP
Time frame: change from baseline in imipenem concentration at 6 hours
pathogens isolated from donors
Time frame: 48 hours before lung procurement
pathogens isolated from recipients
Time frame: 48 hours after lung transplantation
Clinical Pulmonary Infection Score
Time frame: at 72 hours after lung transplantation
Primary graft dysfunction
Time frame: at 72 hours after lung transplantation
Days of mechanical ventilation
Time frame: at 28 days
Intensive Care Unit length of stay
Time frame: at day 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.